<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03715569</url>
  </required_header>
  <id_info>
    <org_study_id>PM52008</org_study_id>
    <nct_id>NCT03715569</nct_id>
  </id_info>
  <brief_title>CNS Infections Effect on the Inner Ear</brief_title>
  <official_title>CNS Infections Effect on the Inner Ear</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordsjaellands Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordsjaellands Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study on patients with CNS infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims and objectives:

      The present proposal aims to improve the outcome from central nervous system infections (CNS)
      by improving the understanding of when and why patients develop hearing loss and other
      neurological sequelae. The investigators will elucidate the temporal development and
      restitution of a sensorineural hearing loss and will clarify if any therapeutic window
      exists, where sequelae can be limited.

      Also the investigators will investigate if communication between cochlea and cerebrospinal
      fluid is a window to the intracranial pressure.

      Background:

      CNS infections remain diseases with high mortality and morbidity. Among survivors from
      bacterial meningitis, 30 % suffer hearing loss or deafness arising from injury to the inner
      ear - the cochlea. From previous work it is known that brain inflammation, brain edema and
      subsequent pressure changes can be transduced to the inner ear due to communication between
      the cochlea and cerebrospinal fluid (CSF).

      The viability of cochlear hair cells can evaluated by non-invasive measurement of otoacoustic
      (OAE) emissions which are low-intensity sounds from the cochlea (OAE).

      Methods and materials:

      The investigators will perform repeated measurements of OAE and Wide Band tympanometry (WBT)
      in all patients admitted with suspicion of a CNS infection. OAE and WBT will be compared to
      intracranial pressure (ICP) measured during lumbar puncture as well as clinical-,
      biochemical- and imaging data. An age-matched control group will be included. At discharge
      and at follow-up patients will receive a neurological, vestibulare examination, cognitive
      test and a regular hearing test.

      Expected outcome and perspectives:

      From repeated measures during a course of disease, the investigators will elucidate the
      development of a hearing loss and clarify if any therapeutic window exists, where sequelae
      can be limited. This is also an opportunity to assess OAE as a non-invasive measure of
      intracranial pressure which is believed to be among the clinical complications responsible
      for a poor outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cochlear damage</measure>
    <time_frame>Day1-90</time_frame>
    <description>Assess the frequency and timely evolution of sensorineural hearing loss by using OAE/WBT and audiometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vestibular function loss</measure>
    <time_frame>Day 1-90</time_frame>
    <description>Assess the frequency of vestibular function loss by using VHit and Caloic tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identifying biochemical markers in CSF during a CNS infection</measure>
    <time_frame>Day 1-90</time_frame>
    <description>Identify biomarkers, such as Cochlin, in CSF and assess their ability to predict sequelae.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive impairment</measure>
    <time_frame>Day 90</time_frame>
    <description>Assess the frequency and serverity of cognitive impariment by using MOCA scores.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>CNS Infection</condition>
  <condition>Inner Ear Hearing Loss</condition>
  <condition>Vestibular Abnormality</condition>
  <condition>Inner Ear Inflammation</condition>
  <condition>Hearing Loss, Sensorineural</condition>
  <arm_group>
    <arm_group_label>Cohort with CNS infections</arm_group_label>
    <description>Otoacoustic emissions (OAE), Wide Band Tympanometry (WBT), Vestibular function tests. Audiometry. MOCA, eGOS are cognitive tests.
Biomarker is a protein found in the inner ear examined in the cerebral fluid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OAE/WBT control: Healthy individuals</arm_group_label>
    <description>Otoacoustic emissions in normal position with head. Otoacoustic emission in different head positions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OAE/WBT control: Systemic infection</arm_group_label>
    <description>Otoacoustic emission during admission</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OAE/WBT control: ICP changes</arm_group_label>
    <description>Otoacoustic emission on patients without an CNS infection before and after elective lumbare puncture with measurement of intracranial pressure (ICP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker control</arm_group_label>
    <description>Inner ear biomarkers in patients without CNS infection. Inner ear fluid examination from patients that underwent elective cochlea implantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Vestibular function</intervention_name>
    <description>Vhit, Caloric test</description>
    <arm_group_label>Cohort with CNS infections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>OAE/WBT</intervention_name>
    <description>Oto acoustic emissions Wide Band Tympanometry</description>
    <arm_group_label>Cohort with CNS infections</arm_group_label>
    <arm_group_label>OAE/WBT control: Healthy individuals</arm_group_label>
    <arm_group_label>OAE/WBT control: ICP changes</arm_group_label>
    <arm_group_label>OAE/WBT control: Systemic infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biomarker</intervention_name>
    <description>Biomarker examination</description>
    <arm_group_label>Biomarker control</arm_group_label>
    <arm_group_label>Cohort with CNS infections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MOCA, eGOS</intervention_name>
    <description>Cognitive tests</description>
    <arm_group_label>Cohort with CNS infections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Audiometry</intervention_name>
    <description>Hearing test</description>
    <arm_group_label>Cohort with CNS infections</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cerebral fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the hospital with a CNS infection.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a CNS infection admitted to the hospital.

        Exclusion Criteria:

          -  Patients with known hearing loss
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Brandt, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of infectious diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisa Skovgaard Jensen, MD</last_name>
    <phone>+4530300969</phone>
    <email>elisa.skovgaard.jensen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Brandt, MD</last_name>
    <email>christian.thomas.brandt.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hillerød hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Brandt, MD</last_name>
      <email>Christian.thomas.brandt.01@reigonh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>October 18, 2018</last_update_submitted>
  <last_update_submitted_qc>October 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nordsjaellands Hospital</investigator_affiliation>
    <investigator_full_name>Elisa Skovgaard Jensen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Labyrinthitis</mesh_term>
    <mesh_term>Central Nervous System Infections</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

